Corium, LLC, a commercial-stage biopharmaceutical company developing novel neuroscience therapies, and Lotus Pharmaceutical, a multinational pharmaceutical company, entered into an exclusive collaboration and license agreement for Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
Lotus' Generic Lenalidomide Receives Approval in the U.S.
Lotus' Generic Nintedanib Esylate Receives Approval in the U.S.
Lotus' Generic Nintedanib Receives Approval in the U.S.
Taiwan's Lotus Pharmaceuticals has announced that its Board of Directors has approved the acquisition of the trademark, marketing authorization, and manufacturing know-how of Pemetrexed 100mg and 500mg under the brand name of Alimta in Taiwan for $62 million from Eli Lilly and Company.
TAIPEI, Taiwan, Nov. 11, 2022 /PRNewswire/ -- Lotus Pharmaceutical (1795: TT), a multinational pharmaceutical company, today reported its financial results for the third quarter ended 30 September 2022.
Under the US$475 million (THB16.46 billion) acquisition deal, Innobic became the largest shareholder of Lotus Pharmaceutical with a 37 per cent stake, and of Adalvo with a 60 per cent stake. The acquisition aims to increase the strength of both Lotus Pharmaceutical and Adalvo as world leaders in pharmaceutical and patent trading industries, as well as increase Thailand’s accessibility to drugs of international standard.
Glenmark and Lotus enter into an exclusive licensing agreement for commercialising Ryaltris in Singapore, Hong Kong and Vietnam. Under the terms of the agreement, Glenmark will be responsible for the manufacturing and supply of Ryaltris, while Lotus International will be responsible for the commercialisation of the product across these markets, Glenmark informed via a statement.
India-based Glenmark Pharmaceuticals has announced that its Swiss subsidiary, Glenmark Specialty, has entered into an exclusive licensing agreement with Lotus International, a wholly-owned subsidiary of Lotus Pharmaceutical Co, for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
Madrid, November 11th , 2021. – PharmaMar S.A. (MSE:PHM) has announced today a licensing agreement with Lotus Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the anticancer drug lurbinectedin in Taiwan.